Publication | Open Access

Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors

Solid TumorsMedicinePharmacologyPharmacotherapyAnti-cancer AgentCancer TreatmentOncologyRadiation Oncology